MedPath

Goserelin

Generic Name
Goserelin
Brand Names
Zoladex
Drug Type
Small Molecule
Chemical Formula
C59H84N18O14
CAS Number
65807-02-5
Unique Ingredient Identifier
0F65R8P09N
Background

Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.

Indication

Goserelin is indicated for:

Associated Conditions
Abnormal Uterine Bleeding, Advanced Breast Cancer, Endometriosis, Advanced carcinoma of the prostate, Stage T2b carcinoma of the prostate, Stage T4 carcinoma of the prostate
Associated Therapies
Palliative Treatment
Clinical Trials
Related News

DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma

Phase 1
Recruiting
Conditions
Fibrolamellar Hepatocellular Carcinoma (FLC)
Interventions
First Posted Date
2020-01-30
Last Posted Date
2024-06-07
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Target Recruit Count
56
Registration Number
NCT04248569
Locations
🇺🇸

Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States

Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients

Phase 4
Conditions
Prostatic Neoplasms
Interventions
Drug: Maximum androgen blockade
First Posted Date
2020-01-30
Last Posted Date
2021-07-29
Lead Sponsor
Wonju Severance Christian Hospital
Target Recruit Count
164
Registration Number
NCT04248621
Locations
🇰🇷

Department of Urology, Chonnam National University, School of Medicine, Gwangju, Korea, Republic of

🇰🇷

Department of Urology, Kyungpook National University, School of Medicine, Daegu, Korea, Republic of

🇰🇷

Department of Urology, Eulji University, College of Medicine, Daejeon, Korea, Republic of

and more 7 locations

Safety, Tolerability and Pharmacokinetic Study of LTI-03 in Healthy Adult Subjects

Phase 1
Completed
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Drug: Placebo
First Posted Date
2020-01-18
Last Posted Date
2022-03-07
Lead Sponsor
Lung Therapeutics, Inc
Target Recruit Count
71
Registration Number
NCT04233814
Locations
🇬🇧

Celerion, Belfast, United Kingdom

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers

Phase 1
Recruiting
Conditions
Cardiovascular Disease
Interventions
First Posted Date
2020-01-02
Last Posted Date
2025-05-11
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Target Recruit Count
64
Registration Number
NCT04216342
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

BMD Alterations and Bone and Muscle Parameters During Menstrual Cessation With GnRH

Completed
Conditions
Muscle
Endometriosis
Bone Metabolism
Bone Density
Interventions
First Posted Date
2019-12-18
Last Posted Date
2021-01-12
Lead Sponsor
424 General Military Hospital
Target Recruit Count
41
Registration Number
NCT04203212
Locations
🇬🇷

424 General Military Hospital, Thessaloníki, Greece

Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer

Phase 1
Recruiting
Conditions
Colorectal Cancer
Pancreatic Cancer
Interventions
First Posted Date
2019-10-07
Last Posted Date
2025-04-29
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Target Recruit Count
30
Registration Number
NCT04117087
Locations
🇺🇸

Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States

A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma

First Posted Date
2019-08-28
Last Posted Date
2020-04-28
Lead Sponsor
Xiangya Hospital of Central South University
Target Recruit Count
30
Registration Number
NCT04072900
Locations
🇨🇳

Xiangya Hospital, Central South University, Changsha, Hunan, China

Pilot Study to Evaluate the Effects of a Generic Goserelin Acetate in Patients With Prostate Cancer

Early Phase 1
Completed
Conditions
Prostate Cancer
Interventions
First Posted Date
2019-08-16
Last Posted Date
2021-05-10
Lead Sponsor
CMX Research
Target Recruit Count
11
Registration Number
NCT04060043
Locations
🇨🇦

Exdeo Clinical Research Inc., Abbotsford, British Columbia, Canada

🇬🇪

Fridon Todua Research Institute of Clinical Medicine, Tbilisi, Georgia

🇨🇦

The Male / Female Health and Research Centre, Barrie, Ontario, Canada

and more 4 locations

A Study of Neoadjuvant Hormone Therapy in Patient With Advanced Prostate Cancer Undergoing Radical Prostatectomy.

Phase 4
Terminated
Conditions
Advanced Prostate Cancer
Interventions
First Posted Date
2019-06-03
Last Posted Date
2022-12-16
Lead Sponsor
AstraZeneca
Target Recruit Count
9
Registration Number
NCT03971110
Locations
🇨🇳

Research Site, Zhengzhou, China

Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma

Phase 2
Recruiting
Conditions
Salivary Gland Carcinoma
Interventions
First Posted Date
2019-05-08
Last Posted Date
2024-10-11
Lead Sponsor
Manish Patel
Target Recruit Count
20
Registration Number
NCT03942653
Locations
🇺🇸

University of Illinois Cancer Center, Chicago, Illinois, United States

🇺🇸

University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States

🇺🇸

University of Michigan Health System, Ann Arbor, Michigan, United States

and more 4 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy